<img src="https://ml.globenewswire.com/Resource/Download/92d7aa70-e37d-4870-bccf-d83b68ba5612?size=2" nborder="0" align="left" hspace="5" vspace="5" title="plus_logo.png" alt="Plus Therapeutics Inc."/>HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to 126 million people. The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use. More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases. This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S. About CNSide Diagnostics, LLC CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=6ZRXgxCTHItiufWhuS1UsTbDOMg3DXWF9-DukVBSQnZm95TYnSSUztpE5lM6HjJncgbZTtV6DHc3FBoKO0QLFkz9iXhs6t2ErWhbVSl5DaA=" rel="nofollow" target="_blank" title="">https://www.cnside-dx.com/.</a> About Plus Therapeutics Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=6ZRXgxCTHItiufWhuS1Usc_cLNBsqIuwkWbNWZPvgdxEpWmTSfNRoegNCK-pAa46dSr_exKRXkK4FuiUyEyswfK_JVCtHExlj-oOWgspuNzKDyPXOQctoFuHuOdv-WcW" rel="nofollow" target="_blank" title="">https://www.plustherapeutics.com.</a> About Elevance Health Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 105 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care  solutions. For  more  information,  please  visit <a href="https://www.globenewswire.com/Tracker?data=AH50D09XhqlnmTOZIwIFCMYVWdJmHgpUcVeTu7pP95PwQnSauP0p4o0prvROUzuAKgnNbad3dlO7_a-HPX6ydQdGQTD2XjcOJC460U1oY-g=" rel="nofollow" target="_blank" title="www.elevancehealth.com">www.elevancehealth.com</a> or  follow us @ElevanceHealth on X and Elevance Health on LinkedIn. Forward-Looking Statements This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates. Investor Contact CORE IR <a href="https://www.globenewswire.com/Tracker?data=AZ0AtJKf36IYzzdWTnNyjDtLlB9S6KMcS9IQMSeStZDejGHpXWL_Rati4SaiHHQp0cotNmQCFfh_NHORf6ho_fbAdTxRrs1I2C2VGbMoyGGfuIWsMtz_FYLfy-lHU0_7" rel="nofollow" target="_blank" title="investor@plustherapeutics.com">investor@plustherapeutics.com</a> <img alt="" src='https://ml.globenewswire.com/media/ODZjZWQxY2ItMTg2ZS00YzliLWFjMzYtNGYwY2U4NDA0YmFjLTEwMTYzNzgtMjAyNi0wNi0yNS1lbg==/tiny/Plus-Therapeutics-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn